Movement Alert｜MicroPort MedBot Rises 8.17% in Regular Trading, Toumai Surgical Robot Global Commercial Installations Surpass 200 Units

Market Focus06-29

On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.

On the news front, the company announced that its core product, the Toumai laparoscopic surgical robot, has achieved over 200 global commercial installations, all with end-customer acceptance reports secured. Global commercial orders have surpassed 300 units with total orders approaching 400, and first-half new orders have already exceeded the full-year total for last year. The latest installation was completed at Spain's HM Hospitales, with year-to-date global new installations ranking first among domestic peers and second globally.

Additionally, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. UBS, JP Morgan, and CITIC Construction Investment have all issued positive ratings, citing strong overseas sales potential and a path toward breakeven in the first half of this year. UBS raised its target price to HKD 35.9 with a Buy rating, projecting a revenue CAGR of 49.5% through 2028.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138563440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138563440","market":"us","top_or_hot":-1,"title":"Movement Alert｜MicroPort MedBot Rises 8.17% in Regular Trading, Toumai Surgical Robot Global Commercial Installations Surpass 200 Units","media":"Market Focus","content":"<p><p>On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.</p><p>On the news front, the company announced that its core product, the Toumai laparoscopic surgical robot, has achieved over 200 global commercial installations, all with end-customer acceptance reports secured. Global commercial orders have surpassed 300 units with total orders approaching 400, and first-half new orders have already exceeded the full-year total for last year. The latest installation was completed at Spain's HM Hospitales, with year-to-date global new installations ranking first among domestic peers and second globally.</p><p>Additionally, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. UBS, JP Morgan, and CITIC Construction Investment have all issued positive ratings, citing strong overseas sales potential and a path toward breakeven in the first half of this year. UBS raised its target price to HKD 35.9 with a Buy rating, projecting a revenue CAGR of 49.5% through 2028.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜MicroPort MedBot Rises 8.17% in Regular Trading, Toumai Surgical Robot Global Commercial Installations Surpass 200 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜MicroPort MedBot Rises 8.17% in Regular Trading, Toumai Surgical Robot Global Commercial Installations Surpass 200 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 10:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.</p><p>On the news front, the company announced that its core product, the Toumai laparoscopic surgical robot, has achieved over 200 global commercial installations, all with end-customer acceptance reports secured. Global commercial orders have surpassed 300 units with total orders approaching 400, and first-half new orders have already exceeded the full-year total for last year. The latest installation was completed at Spain's HM Hospitales, with year-to-date global new installations ranking first among domestic peers and second globally.</p><p>Additionally, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. UBS, JP Morgan, and CITIC Construction Investment have all issued positive ratings, citing strong overseas sales potential and a path toward breakeven in the first half of this year. UBS raised its target price to HKD 35.9 with a Buy rating, projecting a revenue CAGR of 49.5% through 2028.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1138563440","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138563440","pubTimestamp":1782699919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.On the news front, the company announced that its core product, the Toumai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"动静快讯|微创医疗机器人常规交易涨8.17%图迈手术机器人全球商业安装量超200台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"On June 29, MicroPort MedBot rose 8.17% in regular trading, trading at HKD 23.52/share, with turnover of HKD 42.13 million.On the news front, the company announced that its core product, the Toumai laparoscopic surgical robot, has achieved over 200 global commercial installations, all with end-customer acceptance reports secured. Global commercial orders have surpassed 300 units with total orders approaching 400, and first-half new orders have already exceeded the full-year total for last year. The latest installation was completed at Spain's HM Hospitales, with year-to-date global new installations ranking first among domestic peers and second globally.Additionally, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. UBS, JP Morgan, and CITIC Construction Investment have all issued positive ratings, citing strong overseas sales potential and a path toward breakeven in the first half of this year. UBS raised its target price to HKD 35.9 with a Buy rating, projecting a revenue CAGR of 49.5% through 2028.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138563440","isCrawlerRequest":true}